Saturday, 12 May 2018

News: children with MS get their first licensed DMT

It may be old news, but it is very good news; the FDA has just licensed fingolimod as the first DMT for paediatric MS

I am sure parents of children with MS living in the US are relieved that they finally have a licensed therapy for their children. I sincerely hope the EMA now steps up to the mark and does the same in Europe.




As a reminder, the following are the headline results from the study that were presented at ECTRIMS last year. It is clear that fingolimod is far superior to interferon-beta in this younger population.



ProfG    

5 comments:

  1. Wonderful news. Let's hope this is a new era for childhood-onset MS.

    ReplyDelete
  2. Yes it is wonderful news. But autoimmunity takes years to develop. Why are kids getting MS? Surely this is a clue to the cause of MS? Hint hint knudge, knudge wink wink...

    ReplyDelete
    Replies
    1. No need to hint hint.
      Now that it's finally (!) generally acknowledged that Kids get MS, too, there are studies looking into just that.
      And if you ask nicely, Dr. G will tell you his theory of prenatal Vit D3 as perhaps part of that.

      Delete
  3. Prof G, watch this on the BBC: (https://www.bbc.co.uk/iplayer/episode/b0b269sz/victoria-derbyshire-11052018). Skip to the 70 minute mark to see the shocking case of this woman with MS.

    This is Britain in 2018!

    ReplyDelete
  4. https://www.fda.gov/Drugs/DrugSafety/ucm456919.htm FDA Drug Safety Communication: FDA warns about cases of rare brain infection with MS drug Gilenya (fingolimod) in two patients with no prior exposure to immunosuppressant drugs

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.